US based Frontier Biosciences has signed agreement with National Chengdu Centre for Safety Evaluation of Drugs - a full service pre-clinical CRO - established by West China Hospital of the Sichuan University. Frontier will become a shareholder in NCCSED, a GLP certified organisation and the business has just been awarded grants from the Ministry of Science and Technologies in China.
The 80,0000 sq feet state of the art facility has a small SPF animal section and a conventional large animal section, well equipped and staffed by scientists with international CRO experience. Over the last 3 years the centre has carried out studies on more than 60 pre-clinical candidates. Frontier will put in US trained technical and QA staff.